Lung cancer
Conditions
Interventions
Single arm:Postoperative adjuvant therapy was started within 4-12 weeks after operation. Patients received adjuvant therapy with icotinib for 5 years until the end of treatment or disease recurrence/p
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, 2 cm, lymphatic invasion and/or poorly differentiated tumors (micropapillary type, solid/complex glands, cribriform structures), lymphovascular invasion (LVI), vascular tumor thrombus, unknown lymph node status (pNx), and air space dissemination (STAS).
Exclusion criteria
Exclusion criteria: 1. History of mixed small cell carcinoma and non-small cell carcinoma. 2. Incomplete resection (R1/R2) or pneumonectomy. 3. Evidence of severe or uncontrolled systemic disease, or active infection. 4. Have a history of other primary malignancies >= 5 years prior to the first study intervention, except for malignancies for which the purpose of treatment is to cure and there is no known active disease, with a low potential risk of recurrence. 5, Mean resting QTc interval > 470 ms, obtained from three ecg performed at screening. 6. Bone marrow reserve deficiency or organ dysfunction (patients do not meet the following conditions: blood routine examination: HB > 80 g/L; ANC > 1.0 x 10^9/L; PLT > 50 x 10^9/L; blood biochemical examination: ALT and AST < 2.5 times the upper limit of normal; Crea < 1.5 times the upper limit of normal). 7. Previously received any anti-cancer treatment (including chemotherapy, radiotherapy, immunotherapy and EGFR-TKIs) for non-small cell lung cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-year disease-free survival rate;3-year overall survival rate;5-year overall survival rate; | — |
Countries
China
Contacts
Public ContactJiao Peng
Beijing Hospital
Outcome results
None listed